Kiniksa Pharmaceuticals International, plc

Good day and thank you for standing by. Welcome to the Connexa Pharmaceuticals second quarter 2023 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Rachel Frank, Head of Investor Relations.

Thank you, Operator. Good morning, everyone, and thank you for joining Connexus Call to discuss our second quarter 2023 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the Investors and Media section. As for the agenda, our Chief Executive Officer, Sanch K. Patel, will start with an introduction. Ross Mote, our Chief Commercial Officer, will provide an update on our ARCLA commercial execution. Then Mark Ragosa, our Chief Financial Officer, will review our second quarter 2023 financial results. And finally, Sancho will return for closing remarks and kick off the Q&A session, for which Evan Tesari, our Chief Operating Officer, and John Paolini, our Chief Medical Officer, will also be on the line. Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption, Risk Factors Confused in Our FEC Filing. These statements speak only at the date of this presentation, and we undertake no obligation to update such statements, except as required by law. With that, I will turn it over to Saj.

Thanks, Rachel, and good morning, everyone. I'm happy to review our second quarter 2023 financial results today. We've continued to execute across our cardiovascular and autoimmune franchises, positioning us for success and growth in 2023. On the commercial side, Q2 represented another quarter of growth for Arclist, with a net product revenue of $54.5 million. We're encouraged by our commercial execution to date, and we continue to see strong prescriber adoption and patient enrollment in the second quarter. We also remained encouraged by the high patient satisfaction, payer approval rates, and the duration of therapy. Accordingly, we've now raised our 2023 ARCALIS guidance to $220 to $230 million. On the development side, we remain focused on enrolling the Phase II study, KPL-404, which is our CD40 antagonist program in rheumatoid arthritis. This is designed to evaluate the efficacy, dose response, PK, and safety of chronic sub-Q dosing over a duration of 12 weeks. We expect data from this study in the first half of next year. Additionally, we continue to pursue collaborative study agreements with Mavrolimumab to evaluate its potential in rare cardiovascular diseases. This is a molecule that we continue to be excited about, and it has the potential to impact a number of diseases. With that, I'll turn it over to Ross to review our commercial execution of Arclist. Ross.